zonisamide has been researched along with Adverse Drug Event in 9 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide is a broad spectrum antiepileptic drug with multiple mechanisms of action which has been recently approved in the US and Europe as an adjunctive therapy for refractory partial seizures in adults." | 6.47 | Drug safety evaluation of zonisamide for the treatment of epilepsy. ( Cincotta, M; Tramacere, L; Zaccara, G, 2011) |
| "Persistent migraine aura without infarction is a rare but debilitating condition." | 5.62 | Zonisamide as treatment option in persistent migraine aura. ( Broessner, G; Frank, F; Kaltseis, K, 2021) |
| "The multiple drug interactions in which CAIs are involved should be carefully considered when such drugs are used in combination with the drug classes mentioned above, as the risks of developing toxicity and serious side effects if the dosages are not adjusted are high." | 2.53 | Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. ( Supuran, CT, 2016) |
| "Zonisamide is a broad spectrum antiepileptic drug with multiple mechanisms of action which has been recently approved in the US and Europe as an adjunctive therapy for refractory partial seizures in adults." | 2.47 | Drug safety evaluation of zonisamide for the treatment of epilepsy. ( Cincotta, M; Tramacere, L; Zaccara, G, 2011) |
| "Persistent migraine aura without infarction is a rare but debilitating condition." | 1.62 | Zonisamide as treatment option in persistent migraine aura. ( Broessner, G; Frank, F; Kaltseis, K, 2021) |
| "Zonisamide (ZNS) is an anticonvulsant (AC) that contains a sulpha moiety potentially triggering hypersensitivity syndrome reactions (HSR)." | 1.35 | Predicting possible zonisamide hypersensitivity syndrome. ( Cohen, L; Kessas, M; Lee, AW; Malkiewicz, IM; Neuman, MG; Shear, NH, 2008) |
| "Zonisamide was then administered at 10." | 1.35 | Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. ( Boothe, DM; Perkins, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Janković, SM | 1 |
| Kaltseis, K | 1 |
| Frank, F | 1 |
| Broessner, G | 1 |
| Hosohata, K | 1 |
| Inada, A | 1 |
| Oyama, S | 1 |
| Niinomi, I | 1 |
| Wakabayashi, T | 1 |
| Iwanaga, K | 1 |
| Supuran, CT | 1 |
| Neuman, MG | 1 |
| Shear, NH | 1 |
| Malkiewicz, IM | 1 |
| Kessas, M | 1 |
| Lee, AW | 1 |
| Cohen, L | 1 |
| Boothe, DM | 1 |
| Perkins, J | 1 |
| Zaccara, G | 1 |
| Tramacere, L | 1 |
| Cincotta, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for zonisamide and Adverse Drug Event
| Article | Year |
|---|---|
Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects.
Topics: Anticonvulsants; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Epilepsi | 2020 |
Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Antibodies, Monoclonal; | 2016 |
Drug safety evaluation of zonisamide for the treatment of epilepsy.
Topics: Animals; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Isoxazoles; Kidney Calcu | 2011 |
6 other studies available for zonisamide and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Zonisamide as treatment option in persistent migraine aura.
Topics: Adolescent; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Female; Humans; Migraine Diso | 2021 |
Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
Topics: Anticonvulsants; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Exanthema; Fem | 2019 |
Predicting possible zonisamide hypersensitivity syndrome.
Topics: Adult; Age Factors; Aged; Animals; Anticonvulsants; Cell Survival; Diagnostic Techniques and Procedu | 2008 |
Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs.
Topics: Administration, Oral; Animals; Anticonvulsants; Area Under Curve; Biological Availability; Dogs; Dru | 2008 |